GET A CLEAR VIEW OF YOUR PATIENTS’ FUTURE

AvaGen is a new preemptive diagnostic test that detects risk for keratoconus and the presence of corneal dystrophies.

Learn more at www.avellino.com/AvaGen
GENETIC TESTING IS A POWERFUL TOOL FOR YOUR PRACTICE

- Preemptive screening can detect potentially pathogenic variants years before symptoms appear.
- Early detection allows physicians and patients to monitor and strategize for more effective management and plan for a lifetime of healthier vision.
- Including genomic information in a family’s health history can become a valuable tool in determining personal health risk factors.

Genetic testing can also provide timely and beneficial information when recommending refractive surgery options.
TEST WITH THE PREEMPTIVE DIAGNOSTIC THAT REVEALS ANSWERS YEARS EARLIER

AvaGen detects risk factors for keratoconus and the presence of corneal dystrophies, so you and your patients can plan for a brighter future.

Determining risk earlier gives you and your patients a head start on maintaining vision health. AvaGen empowers you to take action, whether that means monitoring, implementing preventive strategies, or initiating treatment.

• Next-generation sequencing examines over 1,000 variants across 75 genes for keratoconus and over 70 mutations for corneal dystrophies

• Proprietary algorithms offer the power to detect very rare variants in multifactorial diseases such as keratoconus

• Non-invasive cheek swab method may be easily administered to patients in the clinic

• Identifies high-risk individuals who are considering refractive surgery, so physicians and patients can make well-informed decisions
CLEAR THE WAY TO A BRIGHTER FUTURE

AvaGen empowers eyecare professionals by giving them the data they need to make better decisions for patients. This could potentially save a patient from future vision loss.

- Genetic tests like AvaGen are the future of medicine and offer more personalized care for patients
- Proactive diagnostics reveal answers earlier, which can help physicians and patients achieve their eye health goals
WHO ARE LIKELY CANDIDATES?

Identifying risk before making important eyecare decisions will help physicians and patients choose the best vision and eye health options.

Candidates include:

- Anyone interested in wearing contact lenses
- Patients considering vision correction surgery, as some vision correction procedures have been associated with the acceleration of protein deposits
- Anyone showing suspicious protein deposit opacities in their cornea
- Patients with a family history of keratoconus and/or corneal dystrophy or who have had a corneal transplant for unknown reasons
- Patients experiencing continually worsening vision over the years
- Anyone without a corneal wound or penetrating eye injury
- Patients who are unsure of their family vision health and genetic history
TEST PATIENTS WITH A CHEEK SWAB

AvaGen supports the test process at every step.
Easily administered.
- Test results in as few as 5 days
- Simple-to-interpret lab results with:
  - A 0 to 100, green-yellow-red scale for each risk factor of keratoconus
  - A positive or negative result for corneal dystrophies
- Readily available patient materials to explain the test
- A complimentary genetic counselor network to support physicians and patients who test positive or are at risk
AvaGen supports the test process at every step. Easily administered. Test results in as few as 5 days. Simple-to-interpret lab results with:

- A 0 to 100, green-yellow-red scale for each risk factor of keratoconus
- A positive or negative result for corneal dystrophies

Readily available patient materials to explain the test. A complimentary genetic counselor network to support physicians and patients who test positive or are at risk.

**ACCESS THE GENETIC COUNSELOR NETWORK FROM AVELLINO**

Avellino offers access to a network of genetic counselors for those patients who receive results of at risk or positive. Counselors work collaboratively with physicians and patients to explain the potential health implications for patients and their relatives.

Genetic counselors can expand on test results and provide helpful information.
PROVIDING GENETIC INSIGHTS TO EMPOWER EYECARE PROFESSIONALS

Learn more and meet our team at www.avellino.com.

About Avellino

A global leader in precision medicine, our mission is to create new opportunities for earlier disease protection through genetic disorder testing, beginning with ophthalmology.

We are moving ahead through the introduction of first-in-class genetic diagnostics, gene therapies, and genetic data to the existing standards of clinical care.

Combining traditional scientific methods with AI-driven genetic data management, Avellino powers more accurate and timely solutions.

Headquartered in Silicon Valley, California, with additional operations in Korea, Japan, China, and the United Kingdom, Avellino is bringing precision medicine and more personalized healthcare to people around the world.

“Genetic medicine is the medicine of the future, but in fact, we already have it today. Avellino has been very successful in screening pathologies of the cornea.”

—John Marshall, Professor of Ophthalmology, Moorfields Eye Hospital, London